Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, ...

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual ...

Additional information, including the accepted abstracts, can be accessed on the website of the ASGCT 2026 Annual Meeting. Presentation materials will be made available on the Posters & Publications ...
Times Argus

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.’s (“Cabaletta Bio” or “Cabaletta”) (Nasdaq: CABA) investigational CAR T cell ...
Seeking Alpha

Exclusive BAC Article: Cabaletta Bio; Rese-Cel Myositis Data At Meetings 2nd Half 2025, Two Other Possible Registration Cohorts In 2025 And Catalysts

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Cabaletta Bio (CABA). The reason why I want to go over this biotech next is because it has ...
Nasdaq

Cabaletta Bio to Present Updated Clinical Data on Rese-cel at 2025 Scientific Conferences

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...